Leading companies spent $1.4 billion upfront on licensing deals and embarked on vast R&D programs. Clinical setbacks mean ...

Presence of KEVs, KEVs Linked to Ransomware, and Insecure Internet Exposure Found to be Pervasive Among BMS, BAS According to ...

Since the first-generation CAR-Ts reached the market several years ago, clinicians have become more adept at handling ...

Results of two phase 2 studies suggest efgartigimod could be a potential treatment for myositis and Sjögren disease in ...

Orally-active mavacamten – which was acquired by BMS when it bought MyoKardia for $13 billion in 2020 – will launch under the Camzyos brand name with a list price of $89,500 per year.

Burrows sees the benefits of such partnerships every day at the GDMS–UK facility in Oakdale, South Wales. The company is working closely with its customers, including Defence Digital, Field Army and ...

A high-tech e-bike will give you a fully digital dashboard. You can see your current speed, total distance, battery life, and ...

A refreshed version of the Tesla Semi was seen testing outside the Semi pilot manufacturing facility in Nevada. And what is ...

Bristol-Myers Squibb faces revenue declines but offers long-term potential via growth drugs. Read what BMY stock has to offer ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

The first half of 2025 has been topsy-turvy for Bristol Myers BMY. Shares of this biotech giant have lost 16.3% year to date compared with the industry ’s decline of 2.7%. The stock has also ...

The RABBIT registry is supported by a joint, unconditional grant from AbbVie, Alfasigma, Amgen, Biocon, Bristol Myers Squibb, ...